OncoMatch/Clinical Trials/NCT07300150
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
Is NCT07300150 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including PT0511 and Cetuximab for colorectal cancer.
Treatment: PT0511 · Cetuximab — The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of PT0511 in adult participants with solid tumors as monotherapy and in combination with cetuximab in participants with colorectal cancer (CRC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Pancreatic Cancer
Non-Small Cell Lung Carcinoma
Tumor Agnostic
Biomarker criteria
Required: KRAS any mutation
any KRAS mutation
Required: KRAS amplification (wild-type)
wild-type (WT) KRAS amplification
Disease stage
Metastatic disease required
Participant has a pathologically documented, locally advanced or metastatic malignancy
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: kras/ras degrader
Lab requirements
Blood counts
Participants with laboratory values indicating inadequate hematology excluded
Kidney function
Participants with laboratory values indicating inadequate renal function excluded
Liver function
Participants with laboratory values indicating inadequate hepatic function excluded
Cardiac function
Clinically significant abnormalities in rhythm, conduction, or morphology of resting ECG; Baseline QTcF >=470 msec
Participants with laboratory values indicating inadequate hematology, hepatic, or renal function. Clinically significant abnormalities in rhythm, conduction, or morphology of resting ECG. Baseline QT interval corrected for heart rate using Fridericia's formula (QTcF) >=470 msec
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Dana-Farber/Massachusetts General Hospital, Inc · Boston, Massachusetts
- New Experimental Therapeutics of San Antonio LLC · San Antonio, Texas
- START - South Texas Accelerated Research Therapeutics, LLC · San Antonio, Texas
- START Mountain Region · West Valley City, Utah
- NEXT Virginia · Fairfax, Virginia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify